Revvity takes on Horizon Discovery in new brand launch

Horizon Discovery has rebranded as Revvity and is now operating under its new name.

The new name means that Horizon Discovery now identifies as Revvity, while maintaining its specific product names. Revvity was previously affiliated with PerkinElmer, Inc, which acquired Horizon Discovery for £296m in 2020.

“The unveiling of Revvity is the capstone of a nearly year-long journey that has transformed who we are and reinforces why our work matters,” said Prahlad Singh, Revvity president and CEO.

Bryan Kipp, VP/GM life sciences strategy & integration at Revvity, told the Cambridge Independent: “Our new brand architecture brings clarity to our portfolio and illustrates how we provide solutions that bridge the gap between life sciences and diagnostics to improve human health. Our aim is to unify the organization and present our offerings under a singular, cohesive, and visionary brand. Today, Revvity represents the entire company.”

Bryan added: “We are excited about the ability for the legacy Horizon organisation to accelerate Revvity’s purpose and vision. This team is a leader and essential collaborator in our research and development solutions department at Revvity.

“As we have since the acquisition of Horizon in 2020, we continue to invest locally to expand our capabilities on site in Cambridge.

“And, in an exciting development, in addition to supporting our legacy Horizon franchises, the Cambridge site will also serve as a Revvity Life Science demonstration site and centre of excellence later this year.”

The company will start trading as Revvity on the NYSE (under RVTY) on May 16. Born from two words, “revolutionize” (rev) and “vita” (vit) meaning “life” in Latin, Revvity delivers end-to-end expertise and solutions from research discovery to development, and diagnosis to cure.